You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
First Genetics will market its F-Genetics NGS System and IVD assays to Russian laboratories for reproductive health testing and cancer diagnostics.
The researchers noted that breast milk bacteria contributed to overall infant gut microbiota variation to a similar extent as other modifiers, such as birth mode.
Analyzing transcriptome data from more than 1,000 cells from 74 embryos, a Johns Hopkins University-led team found aneuploid cells in 80 percent of embryos.
Natera sued Progenity in June but the firm said its Innatal cell-free DNA noninvasive prenatal test does not infringe any of Natera's six patents.
Using exome-enriched RNA sequencing and machine learning, researchers tracked down a set of circulating maternal transcripts for predicting severe early-onset preeclampsia.
Phenotypic clustering identified distinct forms of PCOS with specific gene variants, providing a promising strategy for enhancing the treatment of this syndrome.
Study subjects of both sexes who had low germline mutation rates lived nearly five years longer than individuals with high mutation rates.
Progenity recently agreed to pay millions to three major insurers under settlement agreements related to allegations over undisclosed past business practices.
Under a two-year partnership, the companies plan to discover targets and disease mechanisms for infertility and pregnancy-related conditions, including preeclampsia.
Natera reported $94 million in revenues for the quarter, up from $66.8 million a year ago and beating analysts' consensus estimate of $85 million.
Illumina had sought to exclude the Harmony test from the US Market, while Ariosa had sought to overturn the jury verdict with a post-trial maneuver.
Revenues for the fiscal year totaled £16.6 million ($20.7 million), up from £8.9 million during FY 2019.
The notes will be sold at an initial effective conversion price of about $38.79 per share, approximately a 30 percent premium to Monday's $29.84 per share closing price.
The company is withdrawing its previous financial guidance for 2020, saying that it cannot predict the extent or duration of the impact of the COVID-19 pandemic.
The HRM-based method developed by Chinese researchers could also serve as an alternative genetic test when other methods are unavailable or too expensive.
The US Court of Appeals for the Federal Circuit sent the case, which had been thrown out in December 2018, back to the trial court.
Under the 2018 agreement, the companies had planned to develop cell-free DNA assays for prenatal screening using Qiagen's GeneReader sequencing system.
The firm reported quarterly revenues of $8.4 million and large increases in the number of billable tests delivered in the quarter and over the full year.
The firm plans to use the cash to support commercial expansion of its NIPT to all US states and fund R&D for future diagnostic tests, including liquid biopsies.
AdGeniX started distributing Yourgene's Iona test in France in 2015 and has rapidly grown sales for the test, a trend that is expected to continue.
Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.
Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.
A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.
In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.